0
0
New Delhi, February 6, 2025: The World Health Organization (WHO) has commended India’s leadership in pharmacopoeial standard-setting, recognizing the country’s efforts in ensuring high-quality pharmaceutical standards globally. Dr. Roderico H. Ofrin, WHO Representative to India, lauded India’s contributions while delivering the keynote address at the 15th International Meeting of World Pharmacopoeias (IMWP) on Wednesday.
The three-day event, hosted by the Indian Pharmacopoeia Commission (IPC) under the aegis of the Ministry of Health and Family Welfare, is being held in the national capital in collaboration with the WHO. The meeting, which will continue until February 7, aims to facilitate international cooperation in pharmacopoeial science and regulatory harmonization.
Dr. Ofrin emphasized the significance of regulatory harmonization in safeguarding patient safety and public health. “India’s leadership in pharmacopoeial standard-setting is commendable,” he stated, highlighting the nation’s role in advancing pharmaceutical quality standards.
Union Minister of State for Health and Family Welfare, Anupriya Patel, also reaffirmed India’s commitment to global pharmaceutical standardization and regulatory convergence. She underlined India’s reputation as the “Pharmacy of the World” and stressed the importance of making high-quality medicines accessible to all.
“The IMWP serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization,” Patel noted. She also released the IPC Newsletter 2024 and a special video film that showcases India’s advancements in pharmacopoeial science and the Commission’s efforts in ensuring quality pharmaceutical standards.
Punya Salila Srivastava, Secretary, Ministry of Health and Family Welfare, highlighted the importance of global partnerships in strengthening pharmaceutical quality standards. She reiterated India’s ongoing initiatives in aligning regulatory frameworks with international best practices to ensure the global availability of safe and effective medicines.
The IMWP is set to facilitate discussions on critical areas, including impurity assessment (Q3), implications of ICH Q6 guidelines on pharmacopoeial monograph specifications, and environmental sustainability in pharmaceutical manufacturing. Experts will also deliberate on enhancing collaboration among global pharmacopeias and regulatory bodies, including updates from the Pharmacopoeial Discussion Group (PDG).
The deliberations at the IMWP will reinforce the role of pharmacopeias in ensuring medicine quality, safety, and efficacy. The outcomes of this meeting are expected to shape future collaborations in standard-setting and regulatory harmonization, paving the way for a more robust global pharmaceutical framework.
Disclaimer: This article is based on publicly available information and statements made during the 15th International Meeting of World Pharmacopoeias. It does not reflect any proprietary or confidential data and is intended for informational purposes only.
